Présentation de l'entreprise
Reviva Pharmaceuticals Holdings, Inc. operates as a biopharmaceutical entity dedicated to the discovery, development, and commercialization of next-generation therapeutics aimed at addressing unmet medical needs in the central nervous system, respiratory, inflammatory, and cardiometabolic disease areas. The company functions within the broader Healthcare sector, specifically the Biotechnology industry, which typically involves high-risk research and development cycles with significant potential for breakthrough treatments but also substantial financial uncertainty. As of the latest data, the organization employs 14 individuals and holds a market capitalization of $10.12 million, indicating a very small-scale enterprise with limited operational footprint. The combination of a market cap under $15 million and the absence of reported annual revenue figures suggests that the company is in an early-stage development phase where capital is primarily allocated toward research and clinical trials rather than commercial sales or infrastructure expansion.
Santé financière
The financial statements for Reviva Pharmaceuticals Holdings, Inc. reveal a net income of $-19,864,902 over the trailing twelve-month period, while revenue and EBITDA are not available, indicating that the company has not yet generated significant commercial income to offset its operating expenses. The substantial gap between the reported net income loss and the absence of revenue highlights a cost structure dominated by research and development expenditures typical of early-stage biotechnology firms, where cash outflows are incurred before product launch. Free cash flow stands at $-17,137,860, reflecting significant cash consumption that limits the company's immediate financial flexibility and reliance on external funding sources to sustain operations. All three margin metrics—gross margin, operating margin, and profit margin—are reported at 0.0%, which is consistent with entities that have not yet transitioned from clinical development to profitable commercialization. On the liability side, the company holds $14.44 million in cash against total debt of $406,875, resulting in a debt-to-equity ratio of 4.71, a figure that suggests a highly leveraged balance sheet relative to equity but is mitigated by the substantial cash reserve. The current ratio of 2.08 indicates that the company possesses sufficient liquid assets to cover its short-term obligations more than twice over, providing a buffer against immediate liquidity crises. Return on equity is reported at -420.0% and return on assets at -80.3%, metrics that underscore the aggressive reinvestment strategy and the current inability of management to generate returns on shareholder capital or asset base.
Évaluation de la valorisation
Valuation multiples for Reviva Pharmaceuticals Holdings, Inc. present a complex picture due to the lack of profitability, with the trailing twelve-month P/E ratio listed as N/A and the forward P/E ratio standing at -0.96, implying that future earnings estimates are negative or the company is not expected to reach profitability in the near term. The price-to-book ratio is 0.54, suggesting that the market values the company at less than half of its book value, which often occurs when investors price in the risk of asset impairment or the high likelihood of further dilution before positive earnings are realized. Alternative valuation metrics such as price-to-sales and EV/EBITDA are also unavailable, preventing a direct comparison with peers based on revenue generation or enterprise value efficiency. The stock's price volatility is characterized by a 52-week high of $23.20 and a 52-week low of $0.59, a range that demonstrates extreme price dispersion typical of micro-cap biotechnology stocks subject to high speculation. The beta value of 0.64 indicates that the stock's price movements are less volatile than the broader market, a counter-intuitive finding for a micro-cap stock that may suggest lower systematic risk or a lack of liquidity that dampens price swings.
Growth & Income
Growth metrics for Reviva Pharmaceuticals Holdings, Inc. are currently unavailable for both revenue and earnings on a year-over-year basis, reflecting the company's status as a pre-revenue entity where traditional growth rates have not yet been established. Consequently, the company does not pay dividends, with a dividend yield of N/A and a payout ratio of 0.0%, meaning that all available resources and negative earnings are retained to fund ongoing research and development activities rather than being distributed to shareholders. The absence of a dividend policy is standard for biotechnology companies in the development phase, as the primary objective is capital preservation and growth financing rather than income generation. The overall growth and income profile is defined by a reliance on external capital markets to sustain operations while waiting for potential future commercialization events that could fundamentally alter the company's financial trajectory and valuation multiple.